These findings in conjunction with further immunohistochemistry inferred potential therapeutic promise from targeting HGF, c-Met, MEK/extracellular-regulated kinase (ERK) and/or AKT in a subgroup of UPS/MFH patients. Here, MAP2K7 is linked to undifferentiated pleomorphic sarcoma.